In This Article:
In moves that continue to strengthen its affiliation with the healthcare industry, NVIDIA has added three new companies to its growing list of AI-based partnerships.
The tech company has partnered with clinical research services company IQVIA, genomics specialist Illumina, and Mayo Clinic. Along with a collaboration with research organisation Arc Institute, the collaborations were announced during the JP Morgan Healthcare Conference on 13 January.
Nvidia, the world’s most valuable company with a market cap of $3.33tn, has expanded its presence in the healthcare sector over the past few years. The company states that AI, accelerated computing and biological data coming together is “turning healthcare into the largest technology industry”.
A 2023 report by GlobalData predicts that global revenue for AI platforms across healthcare will reach $18.8bn by 2027, with Nvidia’s technological advancements in the field a key reason for the market’s growth. The newly announced partnerships are the first of 2025 as the tech company looks ahead to a year when it could see its share price soar even higher.
IQVIA will use Nvidia’s AI Foundry – a service that allows companies to build custom generative AI models – to create new solutions in clinical research workflows. IQVIA is also developing agentic AI solutions kitted out with Nvidia’s NIM and Blueprints software that will expedite research and clinical development. Agentic AI perceive, reason, and act within complex and multi-step tasks, and have been referred to as “digital employees”.
During a press briefing ahead of the conference, Nvidia's healthcare vice president Kimberly Powell said: “Initially, we're going to focus on clinical trials. This is the longest, most expensive workflow and drug and medical device development, our partnership will accelerate trial execution while significantly reducing administrative version burden through the deployment of agents of all kinds.”
The partnership with Illumina aims to harness next-generation genomics to enhance drug discovery and human health. As part of the deal, Illumina will use Nvidia’s accelerated computing and AI toolsets for multiomics analysis and workflows. Illumina expanded its reach in the multiomics space with the acquisition of Fluent BioSciences and its single-cell research technology in July 2024. Nvidia said that its technology on Illumina’s platforms will help make analysis and insights of the human genome more accessible to life science researchers and pharmaceutical companies.
Illumina’s chief technology officer Steve Barnard said: “By combining Illumina’s expertise in genomics data and analysis with Nvidia’s powerful AI platforms, we aim to enable pharma and biotech companies to unlock their own multiomics data to uncover transformative insights and improve success rates in developing life-saving therapies.”